Eli Lilly and Company: Alzheimer Disease trials

The registry lists 99 Alzheimer Disease studies with Eli Lilly and Company as lead sponsor. 13 are open to participants now and 63 have results posted.

Early Phase 1 4Phase 1 32Phase 2 28Phase 3 27Phase 4 5No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)Not yet recruitingNCT07843459Phase 1
• A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's DiseaseNot yet recruitingNCT07838155Phase 4
• A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's DiseaseRecruitingNCT07787182Phase 1
• A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's DiseaseRecruitingNCT07787169Phase 1
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).RecruitingNCT07602582Phase 3
• A Study of LY3439539 in Participants With Alzheimer's DiseaseRecruitingNCT07598370Phase 1
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)RecruitingNCT07589595Phase 2
• Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseRecruitingNCT07571161Phase 3
• A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's DiseaseNot yet recruitingNCT07485153
• Epidemiology and Biomarker Study in Alzheimer's DiseaseRecruitingNCT07142954Phase 3
• A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)RecruitingNCT06657768Phase 1
• A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's DiseaseRecruitingNCT06566170
• A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseRecruitingNCT06297590Phase 1
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)Active, not recruitingNCT05738486Phase 3Results posted
• A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)CompletedNCT05108922Phase 3Results posted
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseCompletedNCT05063539Phase 2Results posted
• A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)CompletedNCT04640077Phase 2Results posted
• Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired SubjectsCompletedNCT04474405Early Phase 1Results posted
• Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's DiseaseCompletedNCT04468347Phase 1Results posted
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)Active, not recruitingNCT04437511Phase 3Results posted
• Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's DiseaseCompletedNCT03901105Phase 3Results posted
• A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan InterpretationCompletedNCT03901092Phase 3Results posted
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseCompletedNCT03518073Phase 2Results posted
• Tau Screening Study in Subjects With Early Symptomatic ADCompletedNCT03467477Phase 2Results posted
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)CompletedNCT03367403Phase 2Results posted
• Tau Screening Study in Patients With Early Symptomatic ADCompletedNCT03322462Phase 2Results posted
• A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's DiseaseCompletedNCT03019536Phase 1Results posted
• Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05CompletedNCT02795780Phase 2Results posted
• A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease DementiaTerminatedNCT02791191Phase 2Results posted
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's DiseaseTerminatedNCT02760602Phase 3Results posted
• A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)CompletedNCT02754830Phase 1Results posted
• A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or ADCompletedNCT02624778Phase 1Results posted
• A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)TerminatedNCT02614131Phase 1Results posted
• 18F-AV-1451 Autopsy StudyCompletedNCT02516046Phase 3Results posted
• 18F-AV-1451 High Resolution Autopsy StudyCompletedNCT02350634Phase 1Results posted
• Augmenting Flortaucipir Dosimetry EstimatesCompletedNCT02336360Phase 1Results posted
• A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's DiseaseCompletedNCT02323334Phase 1Results posted
• Clinical Evaluation of Flortaucipir F 18CompletedNCT02278367Phase 2Results posted
• Tau Imaging in Professional FightersCompletedNCT02278354Phase 1Results posted
• Florbetapir Calibration to the Centiloid ScaleCompletedNCT02120664Phase 1Results posted
• The Feasibility of Florbetapir Quantitation in EuropeCompletedNCT02107599Phase 4Results posted
• Evaluation of Reader Training ProcessesCompletedNCT02051790Phase 4Results posted
• Imaging Characteristics of a Follow-up 18F-AV-1451 ScanTerminatedNCT02051764Phase 2Results posted
• Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD SubjectsCompletedNCT02016560Phase 2/3Results posted
• A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired SubjectsCompletedNCT01992380Phase 1Results posted
• The Feasibility of Florbetapir QuantitationCompletedNCT01946243Phase 4Results posted
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus PlaceboTerminatedNCT01900665Phase 3Results posted
• Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.CompletedNCT01890343Phase 2Results posted
• A Study of LY3002813 in Participants With Alzheimer's DiseaseCompletedNCT01837641Phase 1Results posted
• A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's DiseaseCompletedNCT01807026Phase 1Results posted
• Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive DeclineCompletedNCT01703702Phase 4Results posted
• A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)CompletedNCT01662882Phase 2/3Results posted
• A Study of Florbetapir (18F) in Japanese Healthy VolunteersCompletedNCT01660815Phase 1Results posted
• Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)CompletedNCT01565382Phase 3Results posted
• Evaluation of Physician Training Methods to Read Florbetapir-PET ScansCompletedNCT01565369Not applicableResults posted
• Evaluation of PET Scan Timing Relative to AV-45 Injection TimeCompletedNCT01565356Not applicableResults posted
• A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy VolunteersCompletedNCT01565343Phase 1Results posted
• A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy VolunteersCompletedNCT01565330Phase 1Results posted
• A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly VolunteersCompletedNCT01565291Early Phase 1Results posted
• A Study of 18F-AV-45 in Healthy VolunteersCompletedNCT01564706Phase 1Results posted
• Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's DiseaseTerminatedNCT01561430Phase 1/2Results posted
• Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET ScansCompletedNCT01550549Not applicableResults posted
• Clinical Evaluation of Florbetapir F 18 (18F-AV-45)CompletedNCT01518374Phase 2Results posted
• A Non-drug Methods Study in Participants With Alzheimer's DiseaseCompletedNCT01459016Phase 1Results posted
• Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07CompletedNCT01447719Phase 3Results posted
• A Safety Study of LY2886721 Multiple Doses in Healthy SubjectsCompletedNCT01227252Phase 1Results posted
• A Safety Study of LY2886721 Single Doses in Healthy SubjectsCompletedNCT01133405Phase 1Results posted
• Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's DiseaseTerminatedNCT01127633Phase 3Results posted
• A Study of Semagacestat for Alzheimer's PatientsCompletedNCT01035138Phase 3Results posted
• Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)CompletedNCT00857506Phase 2Results posted
• Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the BrainCompletedNCT00857415Phase 3Results posted
• Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal IndividualsCompletedNCT00855868Phase 2Results posted
• Treatment for Aggression and Agitation in Patients With Alzheimer's DiseaseCompletedNCT00843518Phase 2Results posted
• Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With PlaceboCompletedNCT00762411Phase 3Results posted
• A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)CompletedNCT00702143Phase 2Results posted
• Effect of LY450139 on the Long Term Progression of Alzheimer's DiseaseCompletedNCT00594568Phase 3Results posted
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)Active, not recruitingNCT06653153Phase 3
• A Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseaseCompletedNCT06538116Phase 2
• A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)Active, not recruitingNCT05508789Phase 3
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)CompletedNCT05463731Phase 3
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)Active, not recruitingNCT05026866Phase 3
• A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy ParticipantsCompletedNCT04451408Phase 1
• A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)CompletedNCT03720548Phase 1
• A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)Active, not recruitingNCT02951598
• Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research TrialsCompletedNCT02918539
• Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese PhysiciansWithdrawnNCT02029547Not applicable
• A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807TerminatedNCT01733355Early Phase 1
• A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808TerminatedNCT01723488Early Phase 1
• A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)CompletedNCT01503944Phase 1/2
• A Biomarker Study of Solanezumab in Patients With and Without Alzheimer'sCompletedNCT01148498Phase 2
• Effect of LY2062430 on the Progression of Alzheimer's DiseaseCompletedNCT00905372Phase 3
• Effect of LY2062430 on the Progression of Alzheimer's DiseaseCompletedNCT00904683Phase 3
• A Safety Study of LY2811376 Single Doses in Healthy SubjectsCompletedNCT00838084Phase 1
• A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.CompletedNCT00765115Phase 1
• Solanezumab Safety Study in Japanese Patients With Alzheimer's DiseaseCompletedNCT00749216Phase 2
• Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy VolunteersCompletedNCT00329082Phase 2
• Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT00244322Phase 2
• Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's DiseaseCompletedNCT00191009Phase 2/3
• Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's DiseaseCompletedNCT00051909Phase 2